by The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn or Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Plasmid DNA is circular deoxyribonucleic acid (DNA) molecules that can replicate independently of chromosomal DNA. They are important tools in genetic engineering as they may contain genes that can be transferred to other organisms. Plasmid DNA is manufactured for DNA vaccines and gene therapy.
Market key trends:
One of the major trends in the plasmid DNA manufacturing market is increasing investment and funding in gene therapy research and development. Rising demand for gene and cell therapies is compelling market participants to develop large-scale manufacturing capabilities. For instance, in 2021, Danaher Corporation announced plans to invest $350 million over 5 years to help advance plasmid DNA manufacturing capabilities at its gene therapy subsidiary, Pall Corporation. Another key trend is the shift towards continuous manufacturing processes and single-use technologies. Continuous manufacturing allows for enhanced control, reproducibility, and product quality as compared to traditional batch manufacturing.
Market Key Trends:
The Plasmid DNA manufacturing market is witnessing high growth owing to the increasing demand for plasmid DNA in gene therapy and DNA vaccines. Growing R&D in cell and gene therapy coupled with rising investment from key players is fueling the demand for plasmid DNA. Additionally, the development of advanced plasmid DNA manufacturing technologies such as transient gene expression and permanent gene addition is further propelling the market growth.
SWOT Analysis
Strengths: High reproducibility and yields, scalable productions and flexible manufacturing facilities.
Weaknesses: High production cost, challenging downstream processing and quality variations.
Opportunities: Rising funding for cell and gene therapy research and growing biologics market.
Threats: Stringent regulatory norms, biosafety issues and entry of new players.
Key Takeaways
The global Plasmid DNA manufacturing market is expected to witness high growth, exhibiting CAGR of 22% over the forecast period, due to increasing investment in gene therapy development. North America dominated the market in 2023 with a share of over 35%, owing to presence of largest gene therapy pipeline and key market players in the US.
Regional analysis
North America dominates the plasmid DNA manufacturing market, primarily due to robust research funding, rising government initiatives to support genomics industry and presence of key market players in the US. Europe is poised to exhibit a high growth owing to increasing number of clinical trials for cell and gene therapies.
Key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
